Walgreens Boots Alliance Inc

Walgreens Boots Alliance — Q3 2024 Earnings Presentation

36 slides from Walgreens Boots Alliance's earnings presentation, Jun 27, 2024

  1. Slide 1: Third Quarter Fiscal 2024 Results

    Third Quarter Fiscal 2024 Results June 27th, 2024 © 2024 Walgreens Boots Alliance, Inc. All rights reserved.

  2. Slide 2: Safe Harbor and Non-GAAP

    Safe Harbor and Non-GAAP Cautionary Note Regarding Forward-Looking Statements: All statements in this presentation that are not historical are forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These include, without limitat

  3. Slide 3: Foundational strengths and near-term priorities

    Foundational strengths and near-term priorities Foundational strengths Near-term priorities • Trusting relationship with our customers • Navigate retail and pharmacy industry headwinds, and reconfigure businesses • Nationwide presence serving millions daily for future • Deep relationships with payor

  4. Slide 4: Quarterly performance and outlook

    Quarterly performance and outlook • 3Q operational results were below expectations • U.S. Retail Pharmacy performance impacted by challenging pharmacy industry trends and a worse- than-expected consumer environment • U.S. Healthcare delivered a second consecutive quarter of positive adjusted EBITDA1

  5. Slide 5: Performance across business segments

    Performance across business segments U.S. Retail Pharmacy • Comp scripts excluding immunizations1 +1.7% vs. 3Q23, maintaining YTD share in a weaker market Navigating external headwinds • Continued reimbursement pressures net of procurement savings weighed on profitability while delivering cost savin

  6. Slide 6: WBA 3Q24 Financial Highlights

    Reported Fx Constant Fx 3Q24 $ in millions (except EPS) B/(W) vs. 3Q23 B/(W) vs. 3Q231 Sales $36,351 + 2.6% + 2.5% Operating Income GAAP $111 + $588 Adjusted1 $613 (36.1)% (36.3)% WBA 3Q24 Net Earnings GAAP $344 + $225 Financial Adjusted1 $545 (36.6)% (36.5)% Highlights EPS GAAP $0.40 + $0.26 Adjust

  7. Slide 7: WBA YTD24 Financial Highlights

    Reported Fx Constant Fx YTD24 $ in millions (except EPS) B/(W) vs. YTD23 B/(W) vs. YTD231 Sales $110,111 + 6.2% + 5.6% Operating Income GAAP ($13,099) ($6,667) Adjusted1 $2,200 (31.0)% (31.5)% WBA YTD24 Net Earnings GAAP ($5,631) ($2,731) Financial Adjusted1 $2,152 (24.9)% (25.3)% Highlights EPS GAA

  8. Slide 8: U.S. Retail Pharmacy Financials

    B/(W) vs. 3Q24 B/(W) vs. 3Q23 YTD24 $ in millions YTD23 Sales $28,503 + 2.3% $86,308 + 4.4% Adj. gross profit1 $5,022 (6.7)% $16,086 (6.2)% U.S. Retail Adj. SG&A % of sales1 16.2% + 0.1%p 16.7% + 0.7%p Pharmacy Adj. operating income1 $501 (47.9)% $1,947 (37.9)% Financials Adj. operating margin1,2 1.

  9. Slide 9: U.S. Pharmacy

    3Q24 3Q23 YTD24 YTD23 3Q24 vs. 3Q23 | YTD24 vs. YTD23 Total Comparable1 Total Comparable1 Pharmacy sales + 4.4% + 5.7% + 7.7% + 9.1% Prescriptions + 0.5% + 1.6% + 1.0% + 1.9% Prescriptions ex. + 0.6% + 1.7% + 1.2% + 2.1% Immunizations U.S. Pharmacy • Comp pharmacy sales1 +5.7% due to brand inflation

  10. Slide 10: U.S. Retail

    3Q24 YTD24 3Q24 vs. 3Q23 | YTD24 vs. YTD23 Total retail sales (4.0)% (4.9)% Comparable retail sales1 (2.3)% (3.9)% U.S. Retail • Comp retail sales1 down 2.3%, primarily due to a challenging retail environment and continued channel shift, including: − (90) bps impact from lower health & wellness incl

  11. Slide 11: International Financials

    Constant Fx1 Constant Fx1 3Q24 YTD24 B/(W) vs. B/(W) vs. 3Q23 $ in millions YTD23 Sales $5,727 + 1.6% $17,581 + 3.0% Adj. gross profit1 $1,222 + 2.0% $3,720 + 4.0% International Adj. SG&A % of sales1 18.3% (0.8)%p 18.0% (1.1)%p Financials Adj. operating income1 $175 (16.6)% $562 (19.4)% Adj. operati

  12. Slide 12: Boots UK Financials

    3Q24 YTD24 3Q24 vs. 3Q23 | YTD24 vs. YTD23 (constant Fx) Pharmacy comp. sales1 + 5.8% + 2.7% Retail comp. sales1 + 6.0% + 7.1% Boots UK • Strong retail comp sales1 +6.0% with growth across all categories, on top of +13.4% Financials in the prior year ― Growth in Destination Health & Beauty, Flagship

  13. Slide 13: U.S. Healthcare Financials

    B/(W) vs. 3Q24 B/(W) vs. 3Q23 YTD24 $ in millions YTD23 Sales $2,125 + $150 $6,232 + $1,634 Adj. gross profit1 $203 + $89 $560 + $292 Adj. SG&A1 ($225) + $61 ($711) + $40 Adj. operating loss1 ($22) + $150 ($151) + $332 U.S. Healthcare Adj. EBITDA1 $23 + $136 $1 + $347 Financials • 3Q sales led by Vi

  14. Slide 14: Cash Flow

    B/(W) YTD24 $ in millions vs. YTD23 Operating cash flow ($314) ($1,532) Cash capital expenditure ($1,135) $497 Free cash flow1,2 ($1,063) ($1,179) Cash Flow • Operating cash flow negatively impacted by $785M in payments related to legal matters, $386M Boots Pension Plan Annuity premium contributions

  15. Slide 15: Lowering FY24 adj. EPS guidance to $2.80 - $2.95

    Lowering FY24 adj. EPS1 guidance to $2.80 - $2.95 • Reflects recent developments in U.S. Retail Pharmacy business: − Worse-than-expected consumer environment driving higher promotional activity, negatively impacting retail margin − Continuation of challenging pharmacy industry trends affecting margi

  16. Slide 16: Strategic review: Near-term opportunities and actions

    Strategic review: Near-term opportunities and actions • Retail pharmacy business is core to WBA and critical to the future of healthcare • U.S. Pharmacy: Focused on strengthening profitability − Aligning organization for enhanced go-to-market capabilities − Changing the dialogue with partners for be

  17. Slide 17: Q&A

    Q&A 1. Refer to safe harbor and non-GAAP disclosure on slide 2, © 2024 Walgreens Boots Alliance, Inc. All rights reserved. endnotes on slide XX, and reconciliations on slides XX-XX 17

  18. Slide 18: Endnotes

    Endnotes • Please see appendix for reconciliations of non-GAAP financial measures and related disclosures. • The Company presents certain information related to current period operating results in “constant currency,” which is a non-GAAP financial measure. These amounts are calculated by translating

  19. Slide 19: Appendix

    Appendix The information on the following pages provides reconciliations of the supplemental non-GAAP financial measures, as defined under SEC rules, presented in this presentation and discussed on the related conference call to the most directly comparable financial measures calculated and presente

  20. Slide 20: Reconciliation of Non-GAAP financial measures

    Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions, except net debt ratio and lease adjusted net debt ratio) The Company defines net debt ratio as net debt divided by adjusted earnings before interest, tax,

  21. Slide 21: Reconciliation of Non-GAAP financial measures

    Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions) NET LOSS TO ADJUSTED OPERATING INCOME, ADJUSTED EBITDA and ADJUSTED EBITDAR As Reported Twelve months ended May 31, 2024 Net loss (GAAP) $ (12,578) Post-ta

  22. Slide 22: Reconciliation of Non-GAAP financial measures

    Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) 1 Certain legal and regulatory accruals and settlements relate to significant charges associated with certain legal proceedings, including legal defense costs. The Compa

  23. Slide 23: Reconciliation of Non-GAAP financial measures

    Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions) NET EARNINGS (LOSS) TO ADJUSTED NET EARNINGS AND DILUTED NET EARNINGS (LOSS) PER SHARE TO ADJUSTED DILUTED NET EARNINGS PER SHARE Three months ended May 31

  24. Slide 24: Reconciliation of Non-GAAP financial measures

    Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions, except per share amounts) NET EARNINGS (LOSS) TO ADJUSTED NET EARNINGS AND DILUTED NET EARNINGS (LOSS) PER SHARE TO ADJUSTED DILUTED NET EARNINGS PER SHARE

  25. Slide 25: Reconciliation of Non-GAAP financial measures

    Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) 1 Impairment of goodwill, intangibles and long-lived assets recognized in the nine months ended May 31, 2024 resulted from the interim goodwill impairment assessment for

  26. Slide 26: Reconciliation of Non-GAAP financial measures

    Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) 15 Due to the anti-dilutive effect resulting from periods where the Company reports a net loss, the impact of potentially dilutive securities on the per share amounts ha

  27. Slide 27: Reconciliation of Non-GAAP financial measures

    Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions) Three months ended May 31, 2024 Walgreens Boots U.S. Retail Pharmacy1 International U.S. Healthcare Corporate and Other Alliance, Inc. Sales $ 28,503 $ 5,7

  28. Slide 28: Reconciliation of Non-GAAP financial measures

    Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions) Three months ended May 31, 2023 Walgreens Boots U.S. Retail Pharmacy1 International U.S. Healthcare Corporate and Other Alliance, Inc. Sales $ 27,866 $ 5,5

  29. Slide 29: Reconciliation of Non-GAAP financial measures

    Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions) Nine months ended May 31, 2024 Walgreens Boots U.S. Retail Pharmacy1 International U.S. Healthcare Corporate and Other Alliance, Inc. Sales $ 86,308 $ 17,5

  30. Slide 30: Reconciliation of Non-GAAP financial measures

    Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions) Nine months ended May 31, 2023 Walgreens Boots U.S. Retail Pharmacy1 International U.S. Healthcare Corporate and Other Alliance, Inc. Sales $ 82,648 $ 16,4

  31. Slide 31: Reconciliation of Non-GAAP financial measures

    Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) 1 Operating income (loss) for U.S. Retail Pharmacy includes equity earnings in Cencora. As a result of the two-month reporting lag, operating income for the three and ni

  32. Slide 32: Reconciliation of Non-GAAP financial measures

    Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions) OPERATING LOSS TO ADJUSTED EBITDA FOR U.S. HEALTHCARE SEGMENT Three months ended May 31, Nine months ended May 31, 2024 2023 2024 2023 Operating loss (GAAP

  33. Slide 33: Reconciliation of Non-GAAP financial measures

    Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions) EQUITY EARNINGS IN CENCORA Three months ended Nine months ended May 31, 2024 May 31, 2023 May 31, 2024 May 31, 2023 Equity earnings in Cencora (GAAP) $ 44

  34. Slide 34: Reconciliation of Non-GAAP financial measures

    Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions) ADJUSTED EFFECTIVE TAX RATE Three months ended May 31, 2024 Three months ended May 31, 2023 (Loss) Earnings Earnings before before income Income tax income

  35. Slide 35: Reconciliation of Non-GAAP financial measures

    Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions) FREE CASH FLOW Three months ended May 31, Nine months ended May 31, 2024 2023 2024 2023 Net cash provided (used for) by operating activities (GAAP) $ 605 $

  36. Slide 36: Sale-Leaseback Financial Information

    Sale-Leaseback Financial Information Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions) Sale-leaseback financial information Three months ended Nine months ended May 31, 2024 Change vs. 3Q23 May 31, 2024 Change vs. FY23 U.S. Retail Pharmacy Gain on sal

Walgreens Boots Alliance — Q3 2024 Earnings Presentation on 6ix